T. Rowe Price Associates »

Inhibikase Therapeutics shares owned by T. Rowe Price Associates

Quarter-by-quarter ownership of Inhibikase Therapeutics (IKT) shares owned by T. Rowe Price Associates from 13F filings

Historical chart of T. Rowe Price Associates investment in Inhibikase Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Inhibikase Therapeutics held by T. Rowe Price Associates consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Inhibikase Therapeutics by T. Rowe Price Associates

Quarter filed Position value Share count Share price at filing
2026-03-31 $86k 51k 1.69
2025-12-31 $63k 31k 2.06
2025-09-30 $50k 31k 1.63
2025-06-30 $60k 31k 1.96

More positions owned by T. Rowe Price Associates

Nvidia Corporation Comm Stk (NVDA)
Apple Comm Stk (AAPL)
Microsoft Corp Comm Stk (MSFT)
Broadcom Comm Stk (AVGO)
Amazon Comm Stk (AMZN)
Alphabet Comm Stk (GOOGL)
Alphabet Comm Stk (GOOG)
Meta Platforms Comm Stk (META)
Eli Lilly & Co Comm Stk (LLY)
Visa Comm Stk (V)
Netflix Comm Stk (NFLX)
Mastercard Incorporated Comm Stk (MA)
Tesla Comm Stk (TSLA)
Jpmorgan Chase & Co Comm Stk (JPM)
Ge Aerospace Comm Stk (GE)

View all positions for T. Rowe Price Associates

Top funds holding Inhibikase Therapeutics

Sands Capital Ventures
Soleus Capital Management
Trails Edge Capital Partners
Fairmount Funds Management
BlackRock
ADAR1 Capital Management
Blackstone Group
Siren
Commodore Capital
Vanguard Capital Management
Millennium Management
Saturn V Capital Management
Kalehua Capital Management
Spruce Street Capital
Squadron Capital Management

View all funds holding Inhibikase Therapeutics